H. Döhner

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

A. Berrebi, H. Döhner, G. Fingerle-Rowson, 2010, The Lancet.

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

W. Klapper, M. Hallek, S. Stilgenbauer, 2016, The Lancet. Oncology.